Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pfizer PFE-N on Tuesday reported lower first-quarter revenue on slowing sales of COVID-19 drug Paxlovid, and said it was expecting $1.7-billion in additional cost savings as it streamlines its ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another ...

It looks like Pfizer Inc. (NYSE:PFE) is about to go ex-dividend in the next two days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $29 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue estimates decline by 2% due to Part D ...